Drug candidates aren't the only innovations being tested in a wave of trials using new "basket" designs. Three large-scale basket trials are gearing up that will be crucial tests of a paradigm-shifting approach to clinical trial conduct and enrollment that depends on next-generation sequencing (NGS).
The trials – the National Cancer Institute-MATCH study, Novartis AG's SIGNATURE program, and the American Society for Clinical Oncology's TAPUR trial – will take advantage of a revolution in sequencing technology
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?